美沙拉嗪联合益生菌在炎症性肠病治疗中的效果分析  

Analysis of the Effect of Mesalazine Combined with Probiotics in the Treatment of Inflammatory Bowel Disease

作　　者：吴舟[1] WU Zhou(Fuzhou First Hospital,Fuzhou 350009,China)

机构地区：[1]福州市第一医院,福建福州350009

出　　处：《中外医学研究》2021年第23期136-139,共4页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:探讨美沙拉嗪联合益生菌在炎症性肠病治疗中的效果。方法:选取2019年11月-2020年10月笔者所在医院收治的97例炎症性肠病患者,按照随机数字表法将其分为对照组(47例)和观察组(50例)。对照组实施美沙拉嗪治疗,观察组实施美沙拉嗪联合益生菌治疗。比较两组临床症状消失时间、C反应蛋白(CRP)、红细胞沉降率(ESR)、疾病活动指数(DAI)评分、临床疗效、不良反应发生情况。结果:观察组临床症状消失时间(里急后重、腹痛、腹泻、脓血便)均早于对照组,差异有统计学意义(P<0.05)。治疗后,观察组CRP、ESR、DAI评分均低于对照组,差异有统计学意义(P<0.05)。观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论:美沙拉嗪联合益生菌治疗炎症性肠病,可提升临床疗效,且安全性较高。Objective:To investigate the effect of Mesalazine combined with Probiotics in the treatment of inflammatory bowel disease.Method:A total of 97 patients with inflammatory bowel disease admitted in our hospital from November 2019 to October 2020 were selected and divided into the control group(47 cases)and the observation group(50 cases)according to random number table method.The control group was treated with Mesalazine,and the observation group was treated with Mesalazine combined with Probiotics.The clinical symptoms disappearance time,C-reactive protein(CRP),erythrocyte sedimentation rate(ESR),disease activity index(DAI)score,clinical efficacy and occurrence of adverse reactions were compared between the two groups.Result:The disappearance time of clinical symptoms(tenesmus,abdominal pain,diarrhea,pus and blood stool)in the observation group was earlier than that in the control group,and the difference was statistically significant(P<0.05).After treatment,CRP,ESR and DAI scores of the observation group were lower than those of the control group,and the differences were statistically significant(P<0.05).The total effective rate of treatment in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion:Mesalazine combined with Probiotics in the treatment of inflammatory bowel disease can improve clinical efficacy,with high safety.

关 键 词：炎症性肠病 美沙拉嗪 益生菌 不良反应 

分 类 号：R574[医药卫生—消化系统]